Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) Insider Sells 7,000 Shares of Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) insider Joana Goncalves sold 7,000 shares of the company’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $30.61, for a total transaction of $214,270.00. Following the transaction, the insider directly owned 1,518 shares of the company’s stock, valued at approximately $46,465.98. This trade represents a 82.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Oruka Therapeutics Stock Up 13.1%

Shares of Oruka Therapeutics stock traded up $3.69 during trading on Friday, reaching $31.84. 4,762,505 shares of the stock were exchanged, compared to its average volume of 326,495. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of -16.76 and a beta of -0.41. Oruka Therapeutics, Inc. has a 1 year low of $5.49 and a 1 year high of $32.28. The stock’s fifty day moving average is $28.31 and its 200 day moving average is $19.38.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.55) EPS for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.01. Equities analysts forecast that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Jefferies Financial Group initiated coverage on shares of Oruka Therapeutics in a research report on Thursday, November 13th. They set a “buy” rating and a $45.00 price objective on the stock. Guggenheim started coverage on shares of Oruka Therapeutics in a research report on Monday, October 27th. They set a “buy” rating and a $60.00 price target on the stock. Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, November 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Wednesday, October 8th. Finally, Piper Sandler assumed coverage on Oruka Therapeutics in a research report on Thursday. They issued an “overweight” rating and a $75.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $48.88.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ORKA. Legal & General Group Plc bought a new stake in shares of Oruka Therapeutics during the second quarter valued at approximately $28,000. Ameritas Investment Partners Inc. purchased a new position in Oruka Therapeutics in the 2nd quarter worth about $31,000. BNP Paribas Financial Markets lifted its stake in Oruka Therapeutics by 464.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock valued at $31,000 after acquiring an additional 2,306 shares during the period. PNC Financial Services Group Inc. purchased a new stake in shares of Oruka Therapeutics during the 3rd quarter valued at about $39,000. Finally, Russell Investments Group Ltd. bought a new stake in shares of Oruka Therapeutics in the third quarter worth approximately $43,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.